Fig. 4From: Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational seriesThe metastatic para-aortic lymph node pointed with arrow. Notes: a pretreatment of Olaparib. b posttreatment of OlaparibBack to article page